Sign In
Buy CMPGY
$32.39
+0.120 (+0.372%)
At Close: Jun 03, 2026
Real-Estate Giant Compass Under Antitrust Investigation in New York
04:31pm, Wednesday, 03'rd Jun 2026
The state attorney general is investigating Compass after it closed a $1.6 billion acquisition of a rival brokerage firm. Compass shares fell 12% Wednesday.
Compass Therapeutics to Participate in Upcoming June Investor Events
07:30am, Thursday, 28'th May 2026
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to t
Compass Pathways Elects Kathleen Tregoning to Board of Directors
06:30am, Thursday, 28'th May 2026
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal
Compass Pathways: A Trip Worth Taking Before The FDA Verdict
08:39am, Wednesday, 27'th May 2026
COMPASS Pathways (CMPS) is positioned to pioneer COMP360, the first psychedelic drug for treatment-resistant depression (TRD), with expected FDA approval later this year. COMP360 demonstrated primary
Compass: Profit Can Multiply When Housing Market Recovers
12:27am, Friday, 22'nd May 2026
Compass offers exposure to the undervalued housing sector and is now the largest U.S. real estate broker after acquiring Anywhere Real Estate. Despite a 20% YTD decline, COMP is outperforming the flat
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to t
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
03:45pm, Thursday, 21'st May 2026
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc. ("Compass" or the "Company") (NASDAQ: CMPX). Such investors are advise
Compass Pathways Eyes Q4 FDA Filing for Psilocybin Depression Drug After Phase 3 Wins
02:03am, Thursday, 21'st May 2026
Compass Pathways NASDAQ: CMPS executives said the company remains on track to target a fourth-quarter New Drug Application filing for COMP360, its synthetic psilocybin treatment candidate for treatmen
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
06:09pm, Tuesday, 19'th May 2026
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc. (“Compass” or the “Company”) (NASDAQ: CMPX). Such invest
Compass Lexecon Expands Antitrust Expertise With Addition of Two Affiliates
07:30am, Tuesday, 19'th May 2026
WASHINGTON, May 19, 2026 (GLOBE NEWSWIRE) -- Compass Lexecon, a subsidiary of FTI Consulting, Inc. (NYSE: FCN), today announced that Anja Lambrecht, a Professor of Marketing at London Business School
AI/R Compass UOL Advances the Application of AI in DevOps and Earns Recognition from Amazon Web Services
11:56am, Monday, 18'th May 2026
SAN FRANCISCO, May 18, 2026 (GLOBE NEWSWIRE) -- AI/R Compass UOL, a subsidiary of AI/R—a technology company specialized in Agentic AI Engineering— continues to expand the use of artificial intelli
EnergyX Signs Agreement with Compass Minerals to Advance up to 30,000-ton Commercial Lithium DLE Facility in Utah
11:00am, Monday, 18'th May 2026
HIGHLIGHTS: ● EnergyX and Compass Minerals enter into an agreement to advance EnergyX's planned 30,000 tpa commercial-scale direct lithium extraction (DLE) and refinery plant near Utah's Great Sal
Exclusive: Compass Minerals eyes return to lithium market with EnergyX partnership
06:47am, Monday, 18'th May 2026
Compass Minerals plans to jump back into the lithium market by partnering with technology startup EnergyX to extract the battery metal from Utah's Great Salt Lake, a move that comes
Compass Lexecon Adds Leading Competition and Regulatory Economist in London
02:00am, Monday, 18'th May 2026
LONDON, May 18, 2026 (GLOBE NEWSWIRE) -- Compass Lexecon, a subsidiary of FTI Consulting, Inc. (NYSE: FCN), today announced the appointment of Nicola Mazzarotto as an Executive Vice President in Londo
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
11:01pm, Thursday, 14'th May 2026
NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc. ("Compass" or the "Company") (NASDAQ: CMPX). Such investors are advi
